Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Study conclusions do not reflect findings for celecoxib

BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7530.1473-d (Published 15 December 2005) Cite this as: BMJ 2005;331:1473
  1. Joe Feczko, chief medical officer (rscmoppgp-JoeFeczko@pfizer.com)
  1. Pfizer, New York, NY 10017, USA

    EDITOR—The conclusions drawn by Hippisley-Cox et al do not accurately reflect the data as presented.1

    This study found important differences between celecoxib and the studied non-steroidal anti-inflammatory drugs (NSAIDs) in terms of the risk of adverse gastrointestinal effects. Specifically, celecoxib was the only treatment that did …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription